胸痛患者中的冠状动脉粥样硬化、心肌肌钙蛋白与白细胞介素-6:PROMISE试验结果
基于PROMISE试验的1796例稳定性胸痛患者,测量高敏肌钙蛋白I和白细胞介素-6并核心实验室分析CTA的CAD特征。高敏肌钙蛋白与高危斑块、狭窄、CAD-RADS及节段累及评分相关,IL-6仅与狭窄和CAD-RADS相关。校正ASCVD和CAD特征后,IL-6高于中位数与MACE独立相关,在非阻塞性CAD患者中两者同时升高与MACE强烈相关。
要点
- 高敏肌钙蛋白高于中位数1.5 ng/L在单变量中与MACE相关(HR 2.1),校正ASCVD和CAD后不再显著。
- IL-6高于中位数1.8 ng/L在校正ASCVD和高危斑块后仍与MACE相关(HR 1.9)。
- 非阻塞性CAD(狭窄1%-69%)患者中,高敏肌钙蛋白和IL-6同时高于中位数与MACE强烈相关(校正CAD特征后HR 2.5-2.7)。
核心结论
- 高敏肌钙蛋白和IL-6浓度与CAD特征及MACE相关,提示心肌损伤和炎症可能各自参与CAD病理生理通路,该关联在非阻塞性CAD患者中最为明显。
研究设计与样本
- PROMISE试验(前瞻性多中心影像研究评估胸痛,NCT01174550)参与者1796例,年龄60.2±8.0岁,47.5%为男性,中位随访25个月;测量高敏肌钙蛋白I和IL-6浓度,核心实验室分析CTA图像评估CAD特征。
关键影像表现/征象
- 核心实验室分析CTA评估的CAD特征包括显著狭窄(≥70%)、高危斑块、CAD-RADS分类、节段累及评分和冠状动脉钙化评分。
- 校正ASCVD风险的多变量线性回归中,高敏肌钙蛋白与高危斑块、狭窄、CAD-RADS和节段累及评分相关。
- 校正ASCVD风险的多变量线性回归中,IL-6仅与狭窄和CAD-RADS相关。
诊断标准与关键数值
- 高敏肌钙蛋白中位数为1.5 ng/L,高于中位数在单变量分析中与MACE相关(HR 2.1,95%CI 1.3-3.6,P=0.006),校正ASCVD和CAD后不显著。
- IL-6中位数为1.8 ng/L,高于中位数在校正ASCVD和高危斑块后与MACE相关(HR 1.9,95%CI 1.1-3.3,P=0.03),校正CAC后HR 1.9(95%CI 1.0-3.4,P=0.04),校正SIS后HR 1.8(95%CI 1.0-3.2,P=0.04),校正狭窄或CAD-RADS后不显著。
- 非阻塞性CAD(狭窄1%-69%)患者中,高敏肌钙蛋白和IL-6同时高于中位数与MACE强烈相关,校正CAD特征后HR 2.5-2.7。
临床应用与阅片要点
- 在稳定性胸痛患者中,高敏肌钙蛋白和IL-6高于中位数可提示MACE风险,尤其在非阻塞性CAD(狭窄1%-69%)患者中两者同时升高时风险更高。
- 高敏肌钙蛋白与高危斑块、狭窄、CAD-RADS和节段累及评分相关,IL-6仅与狭窄和CAD-RADS相关,阅片时可结合生物标志物理解CAD特征。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Increased inflammation and myocardial injury can be observed in the absence of myocardial infarction or obstructive coronary artery disease (CAD).
OBJECTIVES: The authors determined whether biomarkers of inflammation and myocardial injury-interleukin (IL)-6 and high-sensitivity cardiac troponin (hs-cTn)-were associated with the presence and extent of CAD and were independent predictors of major adverse cardiovascular events (MACEs) in stable chest pain.
METHODS: Using participants from the PROMISE trial, the authors measured hs-cTn I and IL-6 concentrations and analyzed computed tomography angiography (CTA) images in the core laboratory for CAD characteristics: significant stenosis (≥70%), high-risk plaque (HRP), Coronary Artery Disease Reporting and Data System (CAD-RADS) categories, segment involvement score (SIS), and coronary artery calcium (CAC) score. The primary endpoint was a composite MACE (death, myocardial infarction, or unstable angina).
RESULTS: The authors included 1,796 participants (age 60.2 ± 8.0 years; 47.5% men, median follow-up 25 months). In multivariable linear regression adjusted for atherosclerotic cardiovascular disease (ASCVD) risk, hs-cTn was associated with HRP, stenosis, CAD-RADS, and SIS. IL-6 was only associated with stenosis and CAD-RADS. hs-cTn above median (1.5 ng/L) was associated with MACEs in univariable analysis (HR: 2.1 [95% CI: 1.3-3.6]; P = 0.006), but not in multivariable analysis adjusted for ASCVD and CAD. IL-6 above median (1.8 ng/L) was associated with MACEs in multivariable analysis adjusted for ASCVD and HRP (HR: 1.9 [95% CI: 1.1-3.3]; P = 0.03), CAC (HR: 1.9 [95% CI: 1.0-3.4]; P = 0.04), and SIS (HR: 1.8 [95% CI: 1.0-3.2]; P = 0.04), but not for stenosis or CAD-RADS. In participants with nonobstructive CAD (stenosis 1%-69%), the presence of both hs-cTn and IL-6 above median was strongly associated with MACEs (HR: 2.5-2.7 after adjustment for CAD characteristics).
CONCLUSIONS: Concentrations of hs-cTn and IL-6 were associated with CAD characteristics and MACEs, indicating that myocardial injury and inflammation may each contribute to pathways in CAD pathophysiology. This association was most pronounced among participants with nonobstructive CAD representing an opportunity to tailor treatment in this at-risk group. (PROspective Multicenter Imaging Study for Evaluation of Chest Pain [PROMISE]; NCT01174550).
引用
- Ferencik M, Mayrhofer T, Lu MT, et al. Coronary Atherosclerosis, Cardiac Troponin, and Interleukin-6 in Patients With Chest Pain: The PROMISE Trial Results. JACC Cardiovasc Imaging. 2022. PMID: 35926901. doi:10.1016/j.jcmg.2022.03.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。